159 related articles for article (PubMed ID: 36588413)
1. Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
Pianko MJ; Tiutan T; Derkach A; Flynn J; Salvatore SP; Jaffer-Sathick I; Rossi AC; Lahoud O; Hultcrantz M; Shah UA; Maclachlan K; Chung DJ; Shah GL; Landau HJ; Korde N; Mailankody S; Lesokhin AM; Tan C; Scordo M; Jaimes EA; Giralt SA; Usmani S; Hassoun H
Am J Hematol; 2023 Mar; 98(3):421-431. PubMed ID: 36588413
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Cohen C; Royer B; Javaugue V; Szalat R; El Karoui K; Caulier A; Knebelmann B; Jaccard A; Chevret S; Touchard G; Fermand JP; Arnulf B; Bridoux F
Kidney Int; 2015 Nov; 88(5):1135-43. PubMed ID: 26176826
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
4. Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases.
Molina-Andújar A; Tovar N; Cuadrado E; Castrejón de Anta N; Revuelta I; Cucchiari D; Cofan F; Esforzado N; Cibeira MT; Rosiñol L; Bladé J; Diekmann F; Fernández de Larrea C; Quintana LF
Am J Kidney Dis; 2021 Nov; 78(5):755-759. PubMed ID: 33961923
[TBL] [Abstract][Full Text] [Related]
5. Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study.
Kim Y; Park SS; Jeon YW; Yahng SA; Shin SH; Min CK;
Transplant Cell Ther; 2023 Jan; 29(1):55.e1-55.e9. PubMed ID: 36202336
[TBL] [Abstract][Full Text] [Related]
6. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.
Ziogas DC; Kastritis E; Terpos E; Roussou M; Migkou M; Gavriatopoulou M; Spanomichou D; Eleutherakis-Papaiakovou E; Fotiou D; Panagiotidis I; Kafantari E; Psimenou E; Boletis I; Vlahakos DV; Gakiopoulou H; Matsouka C; Dimopoulos MA
Leuk Lymphoma; 2017 Aug; 58(8):1832-1839. PubMed ID: 27967286
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with renal monoclonal immunoglobulin deposition disease.
Kourelis TV; Nasr SH; Dispenzieri A; Kumar SK; Gertz MA; Fervenza FC; Buadi FK; Lacy MQ; Erickson SB; Cosio FG; Kapoor P; Lust JA; Hayman SR; Rajkumar V; Zeldenrust SR; Russell SJ; Dingli D; Lin Y; Gonsalves W; Lorenz EC; Zand L; Kyle RA; Leung N
Am J Hematol; 2016 Nov; 91(11):1123-1128. PubMed ID: 27501122
[TBL] [Abstract][Full Text] [Related]
8. Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience.
Stratta P; Gravellone L; Cena T; Rossi D; Gaidano G; Fenoglio R; Lazzarich E; Quaglia M; Airoldi A; Bozzola C; Monga G; Valente G; Canavese C; Magnani C
Crit Rev Oncol Hematol; 2011 Jul; 79(1):31-42. PubMed ID: 20570173
[TBL] [Abstract][Full Text] [Related]
9. Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment.
Sharma R; Jain A; Jandial A; Lad D; Khadwal A; Prakash G; Nada R; Aggarwal R; Ramachandran R; Varma N; Malhotra P
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):626-634. PubMed ID: 35610119
[TBL] [Abstract][Full Text] [Related]
10. Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant.
Waszczuk-Gajda A; Małyszko J; Vesole DH; Feliksbrot-Bratosiewicz M; Skwierawska K; Krzanowska K; Kobylińska K; Biecek P; Snarski E; Rodziewicz-Lurzyńska A; Kozłowski P; Stefaniak A; Drozd-Sokołowska J; Ziarkiewicz M; Vyas P; Boguradzki P; Mądry K; Biliński J; Tomaszewska A; Maciejewska M; Urbanowska E; Blajer B; Król M; Król M; Zborowska H; Jurczyszyn A; Dwilewicz-Trojaczek J; Jedrzejczak WW; Basak GW
Transplant Proc; 2020 Sep; 52(7):2186-2192. PubMed ID: 32222395
[TBL] [Abstract][Full Text] [Related]
11. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
12. Renal monoclonal immunoglobulin deposition disease: the disease spectrum.
Lin J; Markowitz GS; Valeri AM; Kambham N; Sherman WH; Appel GB; D'Agati VD
J Am Soc Nephrol; 2001 Jul; 12(7):1482-1492. PubMed ID: 11423577
[TBL] [Abstract][Full Text] [Related]
13. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
14. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
15. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-Based Chemotherapy with Autologous Stem Cell Transplantation for Monoclonal Gammopathy of Renal Significance: A Case Report and Literature Review.
Huang J; Sun C; Su H; Zhang C; Xiong J
Kidney Blood Press Res; 2019; 44(4):858-869. PubMed ID: 31352451
[TBL] [Abstract][Full Text] [Related]
17. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.
Ebraheem M; Kumar SK; Dispenzieri A; Jevremovic D; Buadi FK; Dingli D; Cook J; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Binder M; Lin Y; Go RS; Siddiqui MA; Kyle RA; Rajkumar SV; Gonsalves WI; Gertz MA
Transplant Cell Ther; 2022 Nov; 28(11):760.e1-760.e5. PubMed ID: 35940527
[TBL] [Abstract][Full Text] [Related]
18. [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Renal Impairment of Multiple Myeloma Collaborative Study Group
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):871-875. PubMed ID: 29136724
[TBL] [Abstract][Full Text] [Related]
19. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
20. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
